TNB Financial Sells 45 Shares of C.R. Bard, Inc. (NYSE:BCR)

TNB Financial lowered its position in C.R. Bard, Inc. (NYSE:BCR) by 1.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,100 shares of the medical instruments supplier’s stock after selling 45 shares during the period. TNB Financial’s holdings in C.R. Bard were worth $980,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BCR. Cribstone Capital Management LLC bought a new position in shares of C.R. Bard during the first quarter valued at about $130,000. Contravisory Investment Management Inc. boosted its position in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the period. Whittier Trust Co. boosted its position in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the period. ClariVest Asset Management LLC bought a new position in shares of C.R. Bard during the first quarter valued at about $148,000. Finally, SRS Capital Advisors Inc. boosted its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the period. Institutional investors and hedge funds own 85.32% of the company’s stock.

Shares of C.R. Bard, Inc. (BCR) opened at 319.75 on Friday. The company has a 50-day moving average price of $319.00 and a 200-day moving average price of $283.44. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $323.27. The stock has a market cap of $23.24 billion, a price-to-earnings ratio of 41.98 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter in the prior year, the company posted $2.54 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. On average, equities analysts expect that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.

ILLEGAL ACTIVITY WARNING: “TNB Financial Sells 45 Shares of C.R. Bard, Inc. (NYSE:BCR)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/12/tnb-financial-sells-45-shares-of-c-r-bard-inc-nysebcr-updated-updated-updated.html.

Several brokerages recently issued reports on BCR. Cowen and Company boosted their price target on C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research report on Monday, April 24th. BidaskClub raised C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a report on Tuesday, June 6th. Jefferies Group LLC lifted their price objective on C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a report on Monday, April 24th. Finally, Wells Fargo & Company lowered C.R. Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $285.67.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit